Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that PD-1 treatment added to salvage surgery could further decrease the rate of disease progression and improve the survival outcome of patients with resectable locally recurrent nasopharyngeal carcinoma compared with those treated with salvage surgery alone.

Trial Details

NCT ID

NCT04778956

Phase

PHASE3

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Nasopharyngeal Head and Neck Cancer

Interventions

Toripalimab
salvage surgery

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25
Guangzhou, Guangdong, China|23.11667,113.25
Guangzhou, Guangdong, China|23.11667,113.25
Guangzhou, Guangdong, China|23.11667,113.25
Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

The recurrence time is more than 6 months from the end of radiotherapy.
Histologically confirmed recurrent nasopharyngeal carcinoma.
Resectable nasopharyngeal diseases: recurrent T1 (the tumor is confined in nasopharynx, oropharynx and/or nasal cavity without parapharyngeal invol…
Resectable recurrent regional lymph node diseases (recurrent N1-3) without prevertebral fascia, cervical vertebrae, or common/internal carotid arte…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →